Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19987163 | 1.00 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19987242 | 1.00 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL8884584 | 0.82 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL8884585 | 0.82 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19974393 | 0.80 | ALDH1A1 (0.53) | — | |
| SCHEMBL19974371 | 0.80 | ALDH1A1 (0.53) | — | |
| SCHEMBL19987228 | 0.80 | ALDH1A1 (0.53) | — | |
| SCHEMBL9295095 | 0.80 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1376688 | 0.79 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16023839 | 0.79 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453695-B2 | Nucleoside analogues and methods of use thereof | LCB PHARMA INC. (CA) | 2022-09-27 | — | — | US | disclosed |
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | PNP, TYMP, MTAP | SLC28A1 168/4885SLC28A2 208/4885SLC29A1 69/4885 |
| US-11453695-B2 | Nucleoside analogues and methods of use thereof | PNP, RNGTT, MTAP | SLC28A1 176/4885SLC28A2 214/4885SLC29A1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.